Predicting high-risk disease using tissue biomarkers

Current Opinion in Urology

Volumn 23, Issue 3, 2013, Pages 245-251

  Donovan, Michael J ^a   Cordon Cardo, Carlos ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

active surveillance; biomarkers; liquid biopsy; systems pathology

Indexed keywords

BIOLOGICAL MARKER; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53;

CANCER GROWTH; CANCER INVASION; CELL CYCLE REGULATION; CHROMOSOME DELETION; CLINICAL PRACTICE; COMPARATIVE GENOMIC HYBRIDIZATION; DISEASE MARKER; GENE LOSS; GENE REARRANGEMENT; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOMICS; HISTONE METHYLATION; HUMAN; MOLECULAR IMAGING; MOLECULAR PATHOLOGY; ONCOGENE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REVIEW; TIME TO TREATMENT; TUMOR SUPPRESSOR GENE; UBIQUITINATION;

ALGORITHMS; ANIMALS; BIOPSY; DISEASE PROGRESSION; HUMANS; MALE; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; SYSTEMS BIOLOGY; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL; WATCHFUL WAITING;

EID: 84876408558     PISSN: 09630643     EISSN: 14736586     Source Type: Journal    
DOI: 10.1097/MOU.0b013e32835f89cc     Document Type: Review

References (46)

1. Adamy A, Yee DS, Matsushita K, et al. Role of prostate-specific antigen and immediate confirmatory biopsy in predicting progression during active surveillance for low risk prostate cancer. J Urol 2011; 185:477-482.
2. BulM, Zhu X, Valdagni R et al. Active Surveillance for low-risk prostate cancer worldwide: The PRIAS study. Eur Urol 2012. [Epub ahead of print]
3. Yatani R, Kusano I, Shiraishi T, et al. Latent prostatic carcinoma: pathological and epidemiological aspects. Jpn J Clin Oncol 1989; 19:319-326.
4. Abate-Shen C, SHen MM, Gelmann E. Integrating differentiation and cancer: the Nkx3.1 homeobox gene in prostate organogenesis and carcinogenesis. Differentiation 2008; 76:717-727. (Pubitemid 352032747)
5. Padmanabhan A, Gosc EB, Bieberich CJ. Stabilization of the prostatespecific tumor suppressor NKX3.1 by the oncogenic protein kinase Pim-1 in prostate cancer cells. Hum Mol Genet 2013; 22:408-415.
6. Lei Q, Jiao J, Xin L, et al. NKX3.1 stabilizes p53, inhibits AKT activation, and blocks prostate cancer initiation caused by PTEN loss. Cancer Cell 2006; 9:367-378. (Pubitemid 43668733)
7. Lin C, Yang L, Tanasa B, et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009; 139:1069-1083.
8. Netto GJ, Epstein JI. Theranostic and prognostic biomarkers: genomic applications in urological malignancies. Pathology 2010; 42:384-394.
9. Shen MM, Abate-Shen C. Molecular Genetics of prostate cancer: new prospects for old challenges. Genes Dev 2010; 24:1967-2000.
10. Ding Z, Wu C-J, Chu GC, et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011; 470: 269-273.
11. Lewinshtein D, Porter CR, Nelson P. Genomic predictors of prostate cancer therapy outcomes. Expert Rev Mol Diagn 2010; 10:619-6636.
12. Ahmed H. Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Biomark Cancer 2010; 2010:17-33.
13. Min J, Zaslavsky A, Fedele G, et al. An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med 2010; 16:286-294.
14. Shariat SF, Karakiewicz PI, Suardi N, et al. Comparison of nomograms and other methods for predicting outcomes in prostate cancer: a critical analysis of the literature. Clin Cancer Res 2008; 14:4400-4407.
15. Moul JW, Mouraviev V, Sun L, et al. Prostate cancer: the new landscape. Curr Opin Urol 2009; 19:154-160.
16. Cooperberg MR, Konety BR. Management of localized prostate cancer in men over 65 years. Curr Opin Urol 2009; 19:309-314.
17. Andriole GL, Crawford ED, Grubb RL, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-1319.
18. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360:1320-1328.
19. Amin A-O, Kote-Jarai Z, Schumacher FR, Wiklund F. A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and nonaggressive disease. Expert Opin Ther targets 2012; 16:121-130.
20. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310:644-648. (Pubitemid 41528150)
21. Perner S, Mosquera J-M, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007; 31:882-888. (Pubitemid 47165141)
22. Mehra R, Tomlins SA, Shen R, et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol 2007; 20:538-544. (Pubitemid 46631996)
23. Carver BS, Tran J, Gopalan A, et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009; 41:619-624.
24. Carver BS, Tran J, Chen Z, et al. ETS rearrangements and prostate cancer initiation. Nature 2009; 457:E1.
25. Reid AH, Attard G, Ambroisine L, et al. Molecular characterization of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. Br J Cancer 2010; 102:678-684.
26. Han B, Mehra R, Lonigro RJ, et al. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol 2009; 22:1083-1093.
27. Gopalan A, Leversha MA, Sataqopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009; 69:1400-1406.
28. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol 2009; 6:429-439.
29. Hessles D, Smit FP, Verhaegh GW, et al. Detection of TMPRSS2-ERG transcripts and prostate cancer antigen 3 in urinary sediments may improve the diagnosis of prostate cancer. Clin Cancer Res 2007; 13:5103-5108. (Pubitemid 47502077)
30. Penney KL, Pyne S, Schumacher FR, et al. Genome-wide association study of prostate cancer mortality. Cancer Epidemiol Biomarkers Prev 2010; 19:2869-2876.
31. Ishkanian AS, Zafarana G, Thomas J, et al. Array CGH as a potential predictor of radiocurability in intermediate risk prostate cancer. Acta Oncol 2010; 49:888-894.
32. Berger MF, Lawrence MS, Demichelis F, et al. The genomic complexity of primary human prostate cancer. Nature 2011; 470:214-220.
33. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Proc Natl Acad Sci USA 2011; 108:21276-21281.
34. Taylor BS, Schulta N, Hieronymus H, et al. Integrative genomic proofing of human prostate cancer. Cancer Cell 2010; 18:11-22.
35. Markert EK, Mizuno H, Vazques A, Levine AJ. Molecular classification of prostate cancer using curated expression signatures. Proc Natl Acad Sci 2011; 108:21276-21281.
36. Saidi O, Cordon-Cardo C, Costa J. Technology insight: will systems pathology replace the pathologist? Nat Clin Pract Urol 2007; 4:39-45. (Pubitemid 46062985)
37. Costa J. Is clinical systems pathology the future of pathology? Arch Pathol Lab Med 2008; 132:774-776. (Pubitemid 351632853)
38. Cordon-Cardo C, Kotsianti A, Verbel D, et al. Improved prediction of prostate cancer recurrence through systems pathology. J Clin Invest 2007; 117: 1876-1883. (Pubitemid 47036321)
39. Donovan MJ, Costa J, Cordon-Cardo C. Systems pathology: a paradigm shift in the practice of diagnostic and predictive pathology. Cancer 2009; 115:3078-3084.
40. Donovan MJ, Khan FH, Fernandez G, et al. Personalized prediction of tumor response and cancer progression on prostate needle biopsy. J Urol 2009; 1:125-132.
41. Donovan MJ, Hamann S, Clayton M, et al. Systems pathology approach for the prediction of prostate cancer progression after radical prostatectomy. J Clin Oncol 2008; 26:3923-3929.
42. +) identifies favorable-risk prostate cancer for men enrolled in active surveillance program. J Urol 2011; 185:e517-e518.
43. Domingo-Domenech J, Vidal SJ, Rodriguez-Bravo V, et al. Suppression of acquired docetaxel resistance in prostate cancer through depletion of notch and hedgehog-dependent tumor-initiating cells. Cancer Cell 2012; 22:373-388.
44. Anand PK. Exosomal membrane molecules are potent immune response modulators. Commun Integr Biol 2010; 3:405-408.
45. Nilsson J, Skog J, Nordstrand A, et al. Prostate cancer-derived urine exosomes: a novel approach to biomarkers for prostate cancer. Br J Cancer 2009; 100:1603-1607.
46. Diamond E, Lee GY, Akhtar NH, et al. Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol 2012; 2:131.